| Property | Value |
|---|
|
?:abstract
|
-
Artificial Intelligence algorithms are used to identify “progeny†drugs that are similar to the “parents†already being tested against COVID-19 These algorithms assess similarity not only by the molecular make-uof the molecules, but also by the “context†in which specific functional groups are arrangedand/or by three-dimensional distribution of pharmacophores The parent-progeny relationships span same-indication drugs (mostly antivirals) as well as those in which the “progenies†have different and perhaps less intuitive primary indications (e g , immunosuppressant or anti-cancer progenies from antiviral parents) The “progenies†are either already approved drugs or medications in advanced clinical trials – should the currently tested “parent†medicines fail in clinical trials, these “progenies†could be, therefore, re-purposed against the COVID-19 on the timescales relevant to the current pandemic /div
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Suggestions for second-pass anti-COVID-19 drugs based on the Artificial Intelligence measures of molecular similarity, shape and pharmacophore distribution
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}